Diamyd Medical (Germany) Today
| DMN Stock | EUR 0.73 0.02 2.82% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
Diamyd Medical is trading at 0.73 as of the 20th of March 2025. This is a 2.82% up since the beginning of the trading day. The stock's lowest day price was 0.73. Diamyd Medical has more than 63 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. DIAMYD MEDICAL operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. The company has 76.93 M outstanding shares. More on Diamyd Medical AB
Moving together with Diamyd Stock
Moving against Diamyd Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Diamyd Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Diamyd Medical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Diamyd Medical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | Drugs (View all Themes) |
| Business Concentration | Drugs, Biotechnology, Healthcare (View all Sectors) |
Diamyd Medical AB (DMN) is traded on Frankfurt Exchange in Germany and employs 20 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 99.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Diamyd Medical's market, we take the total number of its shares issued and multiply it by Diamyd Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Diamyd Medical AB classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 76.93 M outstanding shares.
Diamyd Medical generates negative cash flow from operations
Check Diamyd Medical Probability Of Bankruptcy
Ownership AllocationDiamyd Medical holds a total of 76.93 Million outstanding shares. Diamyd Medical AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Diamyd Ownership Details
Diamyd Medical AB Risk Profiles
Although Diamyd Medical's alpha and beta are two of the key measurements used to evaluate Diamyd Medical's performance over the market, the standard measures of volatility play an important role as well.
Diamyd Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Diamyd Medical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Diamyd Medical Corporate Management
Elected by the shareholders, the Diamyd Medical's board of directors comprises two types of representatives: Diamyd Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Diamyd. The board's role is to monitor Diamyd Medical's management team and ensure that shareholders' interests are well served. Diamyd Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Diamyd Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ulf MBA | CEO Pres | Profile | |
| Anton Lindqvist | Chief Officer | Profile | |
| Martina Widman | Chief Officer | Profile | |
| Anna BSc | Chief Officer | Profile | |
| Christoph Nowak | Chief Officer | Profile | |
| Eva Karlstrom | Chief Officer | Profile |
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.